ReviewNature reviews. Disease primers2024
Scabies.
Review in Nature reviews. Disease primers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial.BMJ (Clinical research ed.) · 2026Trial
- A Case-Control Study of Risk Factors for Scabies Among Patients Attending Dermatology Clinics in Afghanistan.Health science reports · 2026Article
- Clinical features of 170 Chinese scabies cases and the therapeutic efficacy of sulfur ointment.PLoS neglected tropical diseases · 2026Article
- A LAMP-based assay for rapid detection of human scabies using clinical skin scraping specimens.Scientific reports · 2026Article
- The Impact of Disease-Related Fear and Internalized Stigma on Quality of Life in Patients with Scabies: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Can Artificial Intelligence Support Patient Education in Scabies? A Comparative Analysis of Large Language Model Responses.Healthcare (Basel, Switzerland) · 2026Article
- Global burden and cross-country inequality of infectious skin diseases in children: the Global Burden of Disease Study 2021.International health · 2026Article
- Effective treatment of scabetic nodules with thalidomide: a 5-year retrospective case series.BMC infectious diseases · 2026Article
- Delayed Diagnosis of Scabies: A Case Report.Cureus · 2026Article
- Inhibitory effects of terpenes on Sarcoptes scabiei in the molting stage.BMC veterinary research · 2026Article
- Diverging Global Patterns and Temporal Trends in Inflammatory and Infectious Skin Diseases.Clinical, cosmetic and investigational dermatology · 2026Article
- Controlling recurrent scabies outbreaks in a geriatric hospital: impact of a prevention bundle and lessons from a breakthrough case.Frontiers in public health · 2026Article
- Article
- Real-time imaging on a microwell device allows first insights into the embryonic development of the ubiquitous and notorious scabies parasite.Scientific reports · 2025Article
- Rising scabies incidence and the growing burden on GPs: a retrospective longitudinal study.BJGP open · 2025Article
- Expression profiles of itch markers during scabies infection in a porcine scabies model.PLoS neglected tropical diseases · 2025Article
- Rising scabies incidence in Spain: a retrospective observational analysis of four national data sources, 2011 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Observational
- Tracing the Itch: A Spatiotemporal Analysis of Scabies Rates and Its Risk Factors Using the Global Burden of Disease 2021 Data.Tropical medicine & international health : TM & IH · 2025Article
- Understanding Atopic Dermatitis: Pathophysiology and Management Strategies.Biomolecules · 2025Review
- Prevalence and Clinical Characteristics of Scabies among Patients in Eastern Iran: A Study in Gonabad City, 2024.Journal of arthropod-borne diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scabies is one of the most common and highest-burden skin diseases globally. Estimates suggest that >200 million people worldwide have scabies at any one time, with an annual prevalence of 455 million people, with children in impoverished and overcrowded settings being the most affected. Scabies infection is highly contagious and leads to considerable morbidity. Secondary bacterial infections are common and can cause severe health complications, including sepsis or necrotizing soft-tissue infection, renal damage and rheumatic heart disease. There is no vaccine or preventive treatment against scabies and, for the past 30 years, only few broad-spectrum antiparasitic drugs (mainly topical permethrin and oral ivermectin) have been widely available. Treatment failure is common because drugs have short half-lives and do not kill all developmental stages of the scabies parasite. At least two consecutive treatments are needed, which is difficult to achieve in resource-poor and itinerant populations. Another key issue is the lack of a practical, rapid, cheap and accurate diagnostic tool for the timely detection of scabies, which could prevent the cycle of exacerbation and disease persistence in communities. Scabies control will require a multifaceted approach, aided by improved diagnostics and surveillance, new treatments, and increased public awareness.
Indexed as
Identifiers
39362885What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.